Estland - Estnisch - Ravimiamet

menarini international operations luxembourg s.a. - tramadool+deksketoprofeen - suukaudse lahuse graanulid kotikeses - 75mg+25mg 100tk; 75mg+25mg 10tk; 75mg+25mg 500tk; 75mg+25mg 3tk; 75mg+25mg 15tk; 75mg+25mg 20tk; 75mg+25mg 2tk; 75mg+25mg 50tk

Estland - Estnisch - Ravimiamet

stada arzneimittel ag - tramadool+paratsetamool - õhukese polümeerikattega tablett - 37,5mg+325mg 10tk; 37,5mg+325mg 20tk; 37,5mg+325mg 50tk

Estland - Estnisch - Ravimiamet

cp-pharma handelsgesellschaft mbh - tramadool - närimistablett - 80mg 50tk; 80mg 30tk; 80mg 10tk

Estland - Estnisch - Ravimiamet

cp-pharma handelsgesellschaft mbh - tramadool - närimistablett - 120mg 100tk; 120mg 10tk; 120mg 50tk; 120mg 30tk

Estland - Estnisch - Ravimiamet

cp-pharma handelsgesellschaft mbh - tramadool - närimistablett - 50mg 10tk; 50mg 30tk; 50mg 100tk; 50mg 50tk

Estland - Estnisch - Ravimiamet

cp-pharma handelsgesellschaft mbh - tramadool - närimistablett - 20mg 30tk; 20mg 10tk

Estland - Estnisch - Ravimiamet

pfizer italia s.r.l. - östramustiin - kõvakapsel - 140mg 40tk; 140mg 100tk

Estland - Estnisch - Ravimiamet

salutas pharma gmbh - östramustiin - kõvakapsel - 140mg 100tk

Europäische Union - Estnisch - EMA (European Medicines Agency)

novartis europharm limited - trametiniib - melanoom - antineoplastilised ained - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 ja 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. mitteväikerakk-kopsuvähk (mitteväikerakk-kopsuvähi)trametinib koos dabrafenib on näidustatud ravi täiskasvanud patsientidel, kaugelearenenud mitteväikerakk-kopsuvähi, mille braf v600 mutatsioon.

Europäische Union - Estnisch - EMA (European Medicines Agency)

novartis europharm limited - dabrafenib mesilate - melanoom - antineoplastilised ained - melanomadabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 ja 5. abiaine ravi melanomadabrafenib koos trametinib on näidustatud abiaine ravi täiskasvanud patsientidel, kellel on iii etapp melanoom, mille braf v600 mutatsioon, pärast täielik resektsioon. non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.